| 摘要 |
<p>In vitro method for predicting risk of cancer, course of disease, use of medicines and risk of medicine during the treatment of cancer, comprises assaying one or more gene variation(s) in the promoter region of checkpoint kinase 2 (CHK2) gene on the human chromosome 22q12.1 in a sample of a patient, where the gene variation(s) include(s) polymorphism-7161G-A, polymorphism-7235C-G, polymorphism-10532G-A or polymorphism-10649-(-10621)del29.</p> |
